AKRO - Akero Therapeutics, Inc.

Akero Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

$54.00 (was $54.08)

H.C. Wainwright

Oct 10, 2025 06:05 AM • TheFly

Akero Therapeutics downgraded to Hold from Buy at Jefferies

$56.00 (was $54.15)

Jefferies

Oct 09, 2025 11:19 AM • TheFly

Akero Therapeutics downgraded to Hold from Buy at Canaccord

$54.00 (was $54.19)

Canaccord Genuity

Oct 09, 2025 10:48 AM • TheFly

Akero Therapeutics assumed with a Buy at H.C. Wainwright

$72.00 (was $45.62)

Andrew Fein · H.C. Wainwright

Sep 04, 2025 06:13 AM • TheFly

H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO)

$50.00 (was $26.97)

Ed Arce · H.C. Wainwright

Sep 17, 2024 02:50 AM • StreetInsider

Canaccord Genuity Reiterates Buy Rating on Akero Therapeutics (AKRO)

$56.00 (was $23.43)

Edward Nash · Canaccord Genuity

Jun 12, 2024 03:44 AM • StreetInsider

Akero Therapeutics initiated with an Outperform at Wolfe Research

$40.00 (was $22.99)

Andy Chen · Wolfe Research

Jun 10, 2024 03:16 PM • TheFly

Akero Therapeutics price target lowered to $38 from $50 at Evercore ISI

$38.00 (was $20.30)

Liisa Bayko · Evercore ISI

May 15, 2024 04:06 AM • TheFly

Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward

$40.00 (was $15.04)

Ed Arce · H.C. Wainwright

Oct 11, 2023 11:35 AM • Benzinga

Akero Therapeutics upgraded to Outperform from In Line at Evercore ISI

$50.00 (was $29.05)

Liisa Bayko · Evercore ISI

Sep 13, 2022 04:03 PM • TheFly